Itzhak Rosner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3051749/publications.pdf

Version: 2024-02-01

687363 580821 42 683 13 25 citations h-index g-index papers 44 44 44 895 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever (FMF). European Journal of Human Genetics, 1998, 6, 95-97.	2.8	147
2	The case for hepatitis C arthritis. Seminars in Arthritis and Rheumatism, 2004, 33, 375-387.	3.4	79
3	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
4	Management of Hepatitis C Virus-Related Arthritis. BioDrugs, 2001, 15, 573-584.	4.6	40
5	Acute sacroiliitis. Clinical Rheumatology, 2016, 35, 851-856.	2.2	40
6	Tofacitinib for polyarteritis nodosa: a tailored therapy. Annals of the Rheumatic Diseases, 2016, 75, 2214-2216.	0.9	36
7	A regulatory role for CD72 expression on B cells in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2014, 43, 767-771.	3.4	32
8	Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatology International, 2015, 35, 1625-1630.	3.0	28
9	Colchicine Therapy for Lowâ€Doseâ€Methotrexateâ€Induced Accelerated Nodulosis in a Rheumatoid Arthritis Patient. Journal of Dermatology, 1999, 26, 691-694.	1.2	27
10	Sacroiliitis & Sacroi	3.5	25
11	Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis. Clinical Immunology, 2016, 164, 114-118.	3.2	22
12	Radionuclide Methods in the Diagnosis of Sacroiliitis in Patients with Spondyloarthritis: An Update. Rambam Maimonides Medical Journal, 2016, 7, e0037.	1.0	18
13	Nuchal Fibroma. Journal of Dermatology, 1997, 24, 262-265.	1.2	14
14	Entheseal involvement in systemic disorders. Clinical Rheumatology, 2015, 34, 2001-2010.	2.2	14
15	Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice. European Journal of Rheumatology, 2019, 6, 136-141.	0.6	11
16	The association between elevated serum interleukinâ€22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study. International Journal of Rheumatic Diseases, 2022, 25, 56-60.	1.9	11
17	Crowned dens syndrome, yet another rheumatic disease imposter. Clinical Rheumatology, 2020, 39, 571-574.	2.2	10
18	Effect of infliximab on male fertility: Comment on the article "Fertility in male patients with seronegative spondyloarthropathies treated with infliximab―by Saougou et al., Joint Bone Spine 2013;80, 34–37. Joint Bone Spine, 2014, 81, 102-103.	1.6	9

#	Article	IF	CITATIONS
19	Craniocervical junction involvement in ankylosing spondylitis. European Spine Journal, 2015, 24, 2986-2990.	2.2	9
20	Etanercept treatment-related c-ANCA-associated large vessel vasculitis. Clinical Rheumatology, 2016, 35, 271-273.	2.2	9
21	Cutaneous Eruption in a Patient with Cardiac Myxoma. Journal of Dermatology, 1995, 22, 276-278.	1.2	8
22	Dendritic cells in the pathogenesis of ankylosing spondylitis and axial spondyloarthritis. Clinical Rheumatology, 2019, 38, 1231-1235.	2.2	8
23	Dermatomyositis and Nasopharyngeal Carcinoma. Journal of Dermatology, 1998, 25, 539-543.	1.2	6
24	Ulcerative Colitis and Familial Mediterranean Fever: Can Anakinra Treat Both?. ACG Case Reports Journal, 2019, 6, e00143.	0.4	4
25	Scleroderma renal crisis following Covid-19 infection. Journal of Scleroderma and Related Disorders, 2021, 6, 320-321.	1.7	4
26	Indemonstrable axial spondyloarthritis: does it exist?. Israel Medical Association Journal, 2013, 15, 780-1.	0.1	4
27	Q Fever Risk in Patients Treated with Chronic Antitumor Necrosis Factor-Alpha Therapy. Case Reports in Infectious Diseases, 2016, 2016, 1-3.	0.5	3
28	Semaphorin 3A, a potential immune regulator in familial Mediterranean fever. Clinical and Experimental Rheumatology, 2016, 34, S52-S55.	0.8	3
29	Pseudoseptic Arthritis with Low Synovial Fluid Glucose in Familial Mediterranean Fever. Israel Medical Association Journal, 2017, 19, 461-462.	0.1	3
30	Systemic sclerosis sine scleroderma: Comment on the article by Poormoghim et al. Arthritis and Rheumatism, 2000, 43, 2618-2618.	6.7	2
31	Tocilizumab efficacy in a patient with positive anti-CCP chronic Lyme arthritis. North American Journal of Medical Sciences, 2016, 8, 194.	1.7	2
32	Lysyl Oxidase in Systemic Sclerosis: Getting Under the Skin. Israel Medical Association Journal, 2016, 18, 534-536.	0.1	2
33	Autologous Hematological Stem Cell Transplantation for Systemic Sclerosis in Israel. Israel Medical Association Journal, 2020, 22, 104-110.	0.1	2
34	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39, 51-58.	0.8	2
35	$223\hat{a} \in f$ Sustained response in a phase III study of sarilumab plus nonbiologic disease modifying anti-rheumatic drugs in patients with active, moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Rheumatology, 2018, 57, .	1.9	1
36	Digital Ischemia in a Patient with Recent Influenza A Infection. Israel Medical Association Journal, 2018, 20, 446-447.	0.1	1

#	Article	IF	CITATIONS
37	Production of bone formation-regulating factors by osteoclasts in vitro does not correlate with the radiographic disease progression in patients with ankylosing spondylitis. Joint Bone Spine, 2016, 83, 468-469.	1.6	O
38	Nailfold Video Capillaroscopy: Beyond Systemic Sclerosis. Israel Medical Association Journal, 2019, 21, 499-502.	0.1	0
39	A Study of the Efficacy and Safety of Subcutaneous Injections of Tocilizumab in Adults with Rheumatoid Arthritis. Israel Medical Association Journal, 2020, 22, 557-563.	0.1	O
40	Acute Gout Sacroiliitis. Israel Medical Association Journal, 2021, 23, 191-192.	0.1	0
41	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 51-58.	0.8	0
42	Response to a letter by M. Slouma et al. International Journal of Rheumatic Diseases, 2022, 25, 238-238.	1.9	0